The Endocrine Society's 2023 update to guidelines on management of patients with diabetes at high risk for hypoglycemia, the first since 2009, comes in response to a wide range of advances in the field, the authors wrote, including continuous glucose monitoring devices, algorithm-driven insulin pumps, and new glucagon formulations.
The following 7 questions on the guideline recommendations focus on characteristics of hypoglycemia; the utility of technologies to mitigate risk of hypoglycemia; and the distinctions between therapeutic agents for diabetes which can inform selection to reduce the risk for, and hasten the treatment of hypoglycemia.
Tirzepatide Real-World Benefit Found Greater for CV, Renal Outcomes vs GLP-1 RAs in Adults with T2D
August 12th 2024In a head-to-head real world study, tirzepatide compared with semaglutide resulted in 42%, 20%, and 46% reduced risks for all-cause mortality and major adverse CV and renal events, respectively.